Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias
- PMID: 30270202
- PMCID: PMC6518463
- DOI: 10.1136/jnnp-2018-319089
Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias
Abstract
Objective: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease of motor neurons with a median survival of 2 years. Familial ALS has a younger age of onset than apparently sporadic ALS. We sought to determine whether this younger age of onset is a result of ascertainment bias or has a genetic basis.
Methods: Samples from people with ALS were sequenced for 13 ALS genes. To determine the effect of genetic variation, age of onset was compared in people with sporadic ALS carrying a pathogenic gene variant and those who do not; to determine the effect of family history, we compared those with genetic sporadic ALS and familial ALS.
Results: There were 941 people with a diagnosis of ALS, 100 with familial ALS. Of 841 with apparently sporadic ALS, 95 carried a pathogenic gene variant. The mean age of onset in familial ALS was 5.3 years younger than for apparently sporadic ALS (p=6.0×10-5, 95% CI 2.8 to 7.8 years). The mean age of onset of genetic sporadic ALS was 2.9 years younger than non-genetic sporadic ALS (p=0.011, 95% CI 0.7 to 5.2 years). There was no difference between the mean age of onset in genetic sporadic ALS and familial ALS (p=0.097).
Conclusions: People with familial ALS have an age of onset about 5 years younger than those with apparently sporadic ALS, and we have shown that this is a result of Mendelian gene variants lowering the age of onset, rather than ascertainment bias.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
Conflict of interest statement
Competing interests: AA-C reports consultancies from Mitsubishi Tanabe Pharma, Chronos Therapeutics, Orion Pharma and Cytokinetics. AA-C was chief trial investigator for Orion Pharma (NCT02487407) and Cytokinetics (NCT02496767). All other authors declare no conflicts of interest.
Comment in
-
What does age at onset in ALS tell us about the genetic basis of the disease?J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):250. doi: 10.1136/jnnp-2018-319473. Epub 2018 Oct 24. J Neurol Neurosurg Psychiatry. 2019. PMID: 30355608 No abstract available.
Similar articles
-
Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes.Ann Neurol. 2015 Jan;77(1):100-13. doi: 10.1002/ana.24306. Epub 2014 Nov 27. Ann Neurol. 2015. PMID: 25382069 Free PMC article.
-
The impact of age on genetic testing decisions in amyotrophic lateral sclerosis.Brain. 2022 Dec 19;145(12):4440-4447. doi: 10.1093/brain/awac279. Brain. 2022. PMID: 36162820 Free PMC article.
-
Genetic Epidemiology of Amyotrophic Lateral Sclerosis in Norway: A 2-Year Population-Based Study.Neuroepidemiology. 2022;56(4):271-282. doi: 10.1159/000525091. Epub 2022 May 16. Neuroepidemiology. 2022. PMID: 35576897
-
Genetic epidemiology of amyotrophic lateral sclerosis.Clin Genet. 2003 Feb;63(2):83-101. doi: 10.1046/j.0009-9163.2002.00001.x. Clin Genet. 2003. PMID: 12630951 Review.
-
The epidemiology of amyotrophic lateral sclerosis.Handb Clin Neurol. 2016;138:225-38. doi: 10.1016/B978-0-12-802973-2.00013-6. Handb Clin Neurol. 2016. PMID: 27637961 Review.
Cited by
-
Discovery of Novel Inhibitors against ALS-Related SOD1(A4V) Aggregation through the Screening of a Chemical Library Using Differential Scanning Fluorimetry (DSF).Pharmaceuticals (Basel). 2024 Sep 27;17(10):1286. doi: 10.3390/ph17101286. Pharmaceuticals (Basel). 2024. PMID: 39458929 Free PMC article.
-
Genetics screening in an Italian cohort of patients with Amyotrophic Lateral Sclerosis: the importance of early testing and its implication.J Neurol. 2024 Apr;271(4):1921-1936. doi: 10.1007/s00415-023-12142-x. Epub 2023 Dec 19. J Neurol. 2024. PMID: 38112783
-
C9orf72 intermediate expansions of 24-30 repeats are associated with ALS.Acta Neuropathol Commun. 2019 Jul 17;7(1):115. doi: 10.1186/s40478-019-0724-4. Acta Neuropathol Commun. 2019. PMID: 31315673 Free PMC article.
-
Age of Onset and Length of Survival of Queensland Patients with Amyotrophic Lateral Sclerosis: Details of Subjects with Early Onset and Subjects with Long Survival.Neurodegener Dis. 2022;22(3-4):104-121. doi: 10.1159/000528875. Epub 2022 Dec 30. Neurodegener Dis. 2022. PMID: 36587610 Free PMC article.
-
An Updated Evolutionary and Structural Study of TBK1 Reveals Highly Conserved Motifs as Potential Pharmacological Targets in Neurodegenerative Diseases.Adv Exp Med Biol. 2023;1423:41-57. doi: 10.1007/978-3-031-31978-5_5. Adv Exp Med Biol. 2023. PMID: 37525032
References
-
- Kurland LT, Choi NW, Sayre GP. Implications of incidence and geographic patterns on the classification of amyotrophic lateral sclerosis : Norris FH, Motor neuron diseases: research on amyotrophic lateral sclerosis and related disorders. New York and London: Grune and Stratton, 1968: 28–50.
Publication types
MeSH terms
Supplementary concepts
Grants and funding
- AL-CHALABI/APR15/844-791/MNDA_/Motor Neurone Disease Association/United Kingdom
- MR/L501529/1/MRC_/Medical Research Council/United Kingdom
- MR/L021803/1/MRC_/Medical Research Council/United Kingdom
- SHAW/APR15/933-794/MNDA_/Motor Neurone Disease Association/United Kingdom
- SMITH/APR16/847-791/MNDA_/Motor Neurone Disease Association/United Kingdom
- MRF_MRF-060-0003-RG-SMITH/MRF/MRF/United Kingdom
- JONES/OCT15/958-799/MNDA_/Motor Neurone Disease Association/United Kingdom
- ALCHALABI-TALBOT/APR14/926-794/MNDA_/Motor Neurone Disease Association/United Kingdom
- ALCHALABI-DOBSON/APR14/829-791/MNDA_/Motor Neurone Disease Association/United Kingdom
- G0500289/MRC_/Medical Research Council/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- SHAW/NOV14/985-797/MNDA_/Motor Neurone Disease Association/United Kingdom
- G0600974/MRC_/Medical Research Council/United Kingdom
- SMITH/OCT16/888-792/MNDA_/Motor Neurone Disease Association/United Kingdom
- MR/R024804/1/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous